Hydroxyproline ingestion and urinary oxalate and glycolate excretion.
about
Structural and biochemical studies of human 4-hydroxy-2-oxoglutarate aldolase: implications for hydroxyproline metabolism in primary hyperoxaluriaPrimary hyperoxaluria type III gene HOGA1 (formerly DHDPSL) as a possible risk factor for idiopathic calcium oxalate urolithiasisMetabolism of fructose to oxalate and glycolateExperimental models of renal calcium stones in rodentsMetabolic Interplay between Peroxisomes and Other Subcellular Organelles Including Mitochondria and the Endoplasmic ReticulumNephropathy in dietary hyperoxaluria: A potentially preventable acute or chronic kidney diseaseA Conserved Active Site Tyrosine Residue of Proline Dehydrogenase Helps Enforce the Preference for Proline over Hydroxyproline as the Substrate † ‡Proline dehydrogenase 2 (PRODH2) is a hydroxyproline dehydrogenase (HYPDH) and molecular target for treating primary hyperoxaluriaThe metabolic and ecological interactions of oxalate-degrading bacteria in the Mammalian gut.Evidence for net renal tubule oxalate secretion in patients with calcium kidney stones.Metabolism of primed, constant infusions of [1,2-¹³C₂] glycine and [1-¹³C₁] phenylalanine to urinary oxalateMitochondrial proteomes of porcine kidney cortex and medulla: foundation for translational proteomics.Relevance of dietary protein concentration and quality as risk factors for the formation of calcium oxalate stones in cats.Metabolism of [13C5]hydroxyproline in vitro and in vivo: implications for primary hyperoxaluria.Hydroxyproline metabolism in mouse models of primary hyperoxaluria.Improved methodology to induce hyperoxaluria without treatment using hydroxyproline.Effect of Demographics on Excretion of Key Urinary Factors Related to Kidney Stone Risk4-Hydroxy-2-oxoglutarate aldolase inactivity in primary hyperoxaluria type 3 and glyoxylate reductase inhibitionHydroxyproline metabolism in a mouse model of Primary Hyperoxaluria Type 3Novel findings in patients with primary hyperoxaluria type III and implications for advanced molecular testing strategiesOxalate Formation From Glyoxal in Erythrocytes.Determinants of 24-hour urinary oxalate excretion.Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type IInhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.Metabolomics analysis for hydroxy-L-proline-induced calcium oxalate nephrolithiasis in rats based on ultra-high performance liquid chromatography quadrupole time-of-flight mass spectrometryIncreased protein intake on controlled oxalate diets does not increase urinary oxalate excretion.Response of germ-free mice to colonization with O. formigenes and altered Schaedler flora.Lowering urinary oxalate excretion to decrease calcium oxalate stone disease.Glyoxal formation and its role in endogenous oxalate synthesis.Protein homeostasis defects of alanine-glyoxylate aminotransferase: new therapeutic strategies in primary hyperoxaluria type I.Ascorbic acid intake and oxalate synthesisStudies using a porcine model: what insights into human calcium oxalate stone formation mechanisms has this model facilitated?RNA interference in the treatment of renal stone disease: Current status and future potentials.Oxalate, inflammasome, and progression of kidney diseasePrimary hyperoxaluria: spectrum of clinical and imaging findings.Factors contributing to the variation in feline urinary oxalate excretion rate.Glycolate and 2-phosphoglycolate content of tissues measured by ion chromatography coupled to mass spectrometry.A single-blind, parallel trial of L-hydroxyproline in healthy adult subjects.Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.Auxiliary liver transplant is an effective and safe treatment of primary hyperoxaluria.
P2860
Q24293292-5B82DC7E-7202-432B-9B8B-33155FB7B78FQ24337342-DE8010E9-7315-4519-BF50-EE3B15BE85CBQ24631832-1B704C38-035D-4013-B2FB-2EE9886D3C41Q26765054-9CEAA50C-D928-4200-AA55-355F76E348BBQ26767387-65E6AE4D-F06C-4AF5-BBE8-C7B7E1D0F8D5Q26865804-AC7E5840-ACC1-469B-A395-2F7C56DE9820Q27653411-A2E01CD8-2FF5-4254-A30B-FBDEC19E9ABEQ29147458-751B773A-CA7D-43C4-97CE-41370A4E39EEQ34533525-62AB324D-2DC9-427D-90FA-D633C14BF62FQ34599874-3C555BF1-06E2-48A0-B579-00AAFB292FC7Q35050519-839042A9-00F5-42BC-B1C4-73BADC10BABBQ35663010-A8AF2570-D3A7-4C1F-A3C9-5B196F636A27Q35757534-879B0C9F-1AF3-482F-8D67-C70ADD498E39Q35849447-F9B937D1-1460-429C-882F-354B8273CDF0Q35849482-0685B3FB-39E1-42EF-8773-B0256066643CQ36029292-826E99B1-41DA-4259-9F77-0142D45A320DQ36119367-7FABC545-C69C-4A18-BFEA-7F2FFEDA1180Q36162108-E861FE3C-5D28-4133-A1F8-A07F37099530Q36190922-BC1B43FF-1146-4E8D-A041-9D13688255B0Q36543042-037F9D71-5C06-43AB-BDBE-3EC0F028F2F8Q36678200-91BFAFDC-E6BF-42C0-8B1F-8E13B1A9433FQ36843498-E2D1CE66-5BBA-45EB-880D-2ABFA25C16E9Q36951260-23525005-F44A-419D-AC9C-8882C3FA8FD4Q36951298-E01844FD-7004-4572-B63C-B8D3A39DE9E9Q37117461-6C6AD7A1-FC2D-4E4F-8FEA-B6CA2887BFEEQ37195514-482670D0-F84A-4BCE-9CDC-A7EF14ECE14CQ37405374-5EC3E91F-E027-48B9-A361-18A0425BE30FQ37422038-42432879-5E66-4DC8-970E-282D7DEA993CQ38008378-7948F865-F859-42AA-A3DD-5727BDE2F048Q38129886-6234672F-9666-4036-A1B2-2D6481CD06EFQ38784700-34A7F490-0402-4C66-9AB1-223D2CA7675AQ38788768-CDCEFAED-21E1-4504-82CA-015C964DA49EQ38795112-7BEB5B3E-10F1-46E0-B96B-3053FA5EF737Q38837256-2B35EB2E-64B5-484C-9D09-649DF107F90EQ39008793-ABB9787D-26C3-4A2C-A564-133B6603B29CQ39256203-481AD1A2-26B8-43D8-95FB-835CCA1657CAQ40433684-3F5419E0-BA5E-4A88-97C1-DF125351F419Q42547211-12A299A9-C03C-4003-819B-BF8D080E44E1Q43098007-89CFADD0-69E1-4B3C-A192-6BA48983480AQ43679684-F2AC4BA5-0B9F-42D3-AB44-CDD249D29C98
P2860
Hydroxyproline ingestion and urinary oxalate and glycolate excretion.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Hydroxyproline ingestion and urinary oxalate and glycolate excretion.
@en
type
label
Hydroxyproline ingestion and urinary oxalate and glycolate excretion.
@en
prefLabel
Hydroxyproline ingestion and urinary oxalate and glycolate excretion.
@en
P2860
P356
P1433
P1476
Hydroxyproline ingestion and urinary oxalate and glycolate excretion
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.KI.5001906
P407
P577
2006-10-04T00:00:00Z